| Theme |
For the Effective Eradication of Helicobactor pylori |
| Title |
Helicobacter pylori Eradication Therapy -- First-line Therapy |
| Author |
Ichiro Imoto |
The Third Department of Internal Medicine, Mie University, School of Medicine |
| Author |
Yukiko Taguchi |
The Third Department of Internal Medicine, Mie University, School of Medicine |
| Author |
Nagahito Toyoda |
The Third Department of Internal Medicine, Mie University, School of Medicine |
| Author |
Satoka Oka |
The Third Department of Internal Medicine, Mie University, School of Medicine |
| Author |
Shigehito Nakashima |
The Third Department of Internal Medicine, Mie University, School of Medicine |
| Author |
Michihiko Yamaguchi |
The Third Department of Internal Medicine, Mie University, School of Medicine |
| Author |
Yukihiko Adachi |
The Third Department of Internal Medicine, Mie University, School of Medicine |
| [ Summary ] |
On November 2000, the Japanese Ministry of Health and Welfare approved the H. pylori eradication therapy for patients with peptic ulcer. The recommended first-line therapy is a combination of oral lansoprazole 60mg/day, amoxycillin 1,500mg/day and clarithromycin 400 or 800mg/day for 7 days. This regimen produced a high eradication rate in patients with gastric ulcer (87.5%) and duodenal ulcer (91%) in a multi-center double blind study carried out in Japan. A problem that remains unsolved is the fact that in case of failure to eradicate H.pylori only this regimen is allowed to use for the second-line therapy. Nonetheless, this approval is an important step that will substantially improve the management of peptic ulcer disease in Japan. |